Advertisement

Topics

Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection

2014-07-23 21:08:46 | BioPortfolio

Summary

To determine the outcome and safety of a combined antimicrobial treatment involving daptomycin and surgical approach involving retention or short-interval two-stage exchange of the implant. Patients with hip, knee and shoulder Prosthetic Joint Infection (PJI) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included and followed during 2 years.

Description

In this prospective open observational clinical study (phase 2) patients with hip, knee and shoulder PJI (as defined below) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included. An informed consent will be obtained prior to patient inclusion. Medical records will be prospectively abstracted for demographic characteristics, clinical, radiographic, laboratory and microbiologic data using a standardized case report form (CRF). After inclusion, intravenous daptomycin 10 mg/kg (calculated as actual body weight) is given once daily for 2-3 weeks, followed by oral rifampin-containing antibiotics for a total of 3 months (as outlined below).

Two surgical modalities will be applied according to the PJI treatment algorithm:

- Open debridement and retention of the prosthesis (change of mobile parts): daptomycin will be combined with rifampin.

- Two-stage exchange of the prosthesis with a short interval (2-3 weeks): daptomycin of the prosthesis: daptomycin will be used alone.

The decision whether the implant will be retained or removed is based on objective criteria of the treatment algorithm and is not subject to bias. All consecutive patients with a staphylococcal PJI infection of the hip, knee or shoulder prosthesis will be included, if no exclusion criterion is present, obviating the selection bias. Since not many specialized institutions are treating patients with PJI, we expect low number of patients.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Staphylococcal Infections

Intervention

Daptomycin

Location

Centre hospitaliere universitaire vaudois (CHUV)
Lausanne
Vaud
Switzerland
1011

Status

Not yet recruiting

Source

Centre Hospitalier Universitaire Vaudois

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:08:46-0400

Clinical Trials [272 Associated Clinical Trials listed on BioPortfolio]

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

The goals of the study are to evaluate the feasibility of using daptomycin as a prophylactic antimicrobial agent in patients undergoing cardiac surgery, to determine the rates of surgical ...

Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of ...

Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections

This is a multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of HDSD daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- SSP...

An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants

This is a safety and pharmacokinetic study of single-dose daptomycin in infants > 48 hours and < 120 days of age with suspected systemic infections. The investigators will enroll a total ...

PubMed Articles [3413 Associated PubMed Articles listed on BioPortfolio]

Comparative evaluation of VITEK® 2 and three commercial gradient strip assays for daptomycin susceptibility testing of Staphylococcus aureus.

MRSA remains a major cause of severe nosocomial infections and the increased use of vancomycin and daptomycin for MRSA treatment over the last decade has led to the isolation of MRSA strains with decr...

DAPTOMYCIN TREATMENT IN VASCULAR GRAFT GRAM-POSITIVE INFECTIONS.

Daptomycin is a bactericidal antibiotic approved for the treatment of skin and soft tissue infections and right-side endocarditis. However, there is a lack of published data outlining its usefulness i...

Daptomycin.

Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of Gram-positive infections including complicated skin and skin structure infections, right-sided infective endocarditis, bacteraem...

Comparison of Risk Factors and Outcomes of Daptomycin-Susceptible and -Nonsusceptible Vancomycin-Resistant Enterococcus faecium Infections in Liver Transplant Recipients.

Vancomycin-resistant Enterococcus faecium (VRE) infections are common in liver transplant recipients (LTRs). Daptomycin (DAP) is an important treatment for such infections; however, DAP-nonsusceptible...

A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections.

There is limited clinical evidence to support the combination of daptomycin and beta-lactam antibiotics (DAP + BLA) for treatment of vancomycin-resistant enterococci (VRE) bloodstream infections (...

Medical and Biotech [MESH] Definitions

Infections with bacteria of the genus STAPHYLOCOCCUS.

Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.

A diffuse, non-pitting induration of the skin of unknown etiology that occurs most commonly in association with diabetes mellitus, predominantly in females. It typically begins on the face or head and spreads to other areas of the body, sometimes involving noncutaneous tissues. Often it is preceded by any of various infections, notably staphylococcal infections. The condition resolves spontaneously, usually within two years of onset. (From Dorland, 27th ed)

An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.

Poisoning by staphylococcal toxins present in contaminated food.

More From BioPortfolio on "Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Trial